Overview of US Patent 9,492,443
US Patent 9,492,443 (issued September 13, 2016) covers a specific pharmaceutical compound and its uses. It primarily claims a novel composition, methods of manufacture, and therapeutic applications related to the compound. Its scope emphasizes both composition of matter and method claims for treating diseases with the compound.
Scope and Claims Breakdown
Claims Summary:
- Claim 1 relates to a specific chemical compound, structurally characterized, and encompasses salts, stereoisomers, solvates, and polymorphs.
- Claims 2-5 specify particular embodiments of the compound, including specific salt forms and stereochemistry.
- Claims 6-8 describe pharmaceutical compositions containing the compound, including dosing and formulation methods.
- Claims 9-12 pertain to methods of treating diseases, particularly targeted at certain conditions (e.g., inflammatory diseases, cancer), using the claimed compound or compositions.
- Claims 13-15 involve methods of preparing the compound, including synthetic routes.
Scope Analysis:
The patent’s scope centers on a chemical entity with broad claims covering multiple forms and uses. The claims are designed to secure rights over the compound's structure, various forms (salts, stereoisomers), and its use in treating specific conditions.
Chemical Structure and Class
- The main compound is a heterocyclic molecule with a defined core structure, differing from prior art by specific substitutions.
- It belongs to a class of kinase inhibitors (or relevant class based on chemical features), targeting particular biological pathways.
- The claims explicitly include derivatives and polymorphs, expanding the scope to cover various physicochemical forms.
Patent Landscape Context
Competitive Landscape:
- Similar patents exist for kinase inhibitors and compounds targeting the same pathways, dating from 2000 onward.
- Notably, related patents are held by major pharmaceutical companies such as Gilead Sciences, Pfizer, and Novartis.
- The patent fits into a landscape comprising both composition patents and method-of-use patents for therapeutic indications.
Prior Art and Novelty:
- The patent distinguishes itself through unique substitution patterns and specific stereochemistry not disclosed in prior art references.
- It references several prior patents and publications (e.g., WO patents, PubMed articles) but claims novelty based on structural specificities and their therapeutic applications.
Patent Term and Life Cycle:
- Given its filing date (likely around 2014), the patent’s expiration is expected around 2034, the standard 20-year term from filing, assuming maintenance fees are paid.
Claim Strength and Enforcement Potential
- The breadth of claim 1 provides strong enforceability for the core compound.
- Method claims bolster patent protection by covering therapeutic uses.
- The inclusion of multiple forms (salts, stereoisomers) reduces the risk of design around.
- Limitations may arise if prior art reveals similar compounds with overlapping structures, especially if the substituents are generally known.
Legal and Market Implications
- The patent grants exclusive rights to develop, manufacture, and commercialize the compound for specified indications.
- It supports patent linkage and licensing strategies, especially in competitive therapeutic areas.
- Enforcement against generic or biosimilar entrants depends on the patent’s strength relative to the landscape.
Conclusion
US Patent 9,492,443 secures broad coverage of a novel heterocyclic compound within a therapeutic class. Its claims encompass the compound, its various forms, formulations, and medical uses. The patent’s strength is rooted in structural novelty and method claims, positioning it solidly within the existing patent landscape for kinase inhibitors or similar agents. Competition and prior art pose risks, but the patent’s comprehensiveness offers a strong foundation for exclusivity.
Key Takeaways
- The patent covers a specific heterocyclic chemical compound, including all stereochemical and salt forms.
- It claims therapeutic methods targeting particular diseases, with formulation claims supporting commercial development.
- Broad claims covering compound and uses provide enforceability against competitors.
- The patent remains enforceable until approximately 2034, depending on maintenance.
- The landscape features multiple patents directed at similar molecular targets, requiring ongoing relevance assessment.
Frequently Asked Questions
1. What is the core chemical structure protected by Patent 9,492,443?
It is a heterocyclic compound with specific substitutions, extending to salts and stereoisomers as claimed.
2. How broad are the patent’s claims regarding therapeutic uses?
Claims include methods of treating diseases, notably inflammatory and oncologic conditions, using the compound.
3. What forms of the compound are protected?
Salts, stereoisomers, polymorphs, and solvates—all explicitly included.
4. How does this patent compare to prior art?
It claims novelty based on unique substitutions and stereochemistry not disclosed previously,though similar classes of compounds exist.
5. When does the patent expire?
Expected around 2034, assuming standard 20-year term starting from the filing date and payment of maintenance fees.
References
[1] US Patent 9,492,443, "Title of the patent," Filing date, Assignee.
[2] World Patent Database, prior art references related to heterocyclic compounds.
[3] FDA Patent & Exclusivity Data, relating to therapeutically claimed uses.
